MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has been granted a U.S. patent for the use of its leading compound, buntanetap, in the treatment and prevention of acute brain and nerve injuries. This development offers global protection for the drug, which is now covered in the U.S., European Union, Japan, and other key regions worldwide.
The patent focuses on buntanetap’s mechanism of reducing neurotoxicity and mitigating damage caused by neurodegenerative processes. These attributes make it a promising treatment option for conditions such as stroke, traumatic brain injury, ischemia, micro infarcts, and other forms of acute neural damage.
“Nerve cells are inherently delicate and susceptible to structural damage upon physical impact. Buntanetap works by targeting the neurotoxic pathways that contribute to this damage, providing a potential path to protect and restore neuronal health,” said Maria Maccecchini, Ph.D., Founder, President and CEO of Annovis Bio.
Already under investigation for chronic conditions like Alzheimer’s and Parkinson’s diseases, Buntanetap’s expanded intellectual property marks a significant breakthrough, positioning the drug to potentially address a broader spectrum of neurodegenerative disorders.
The U.S. Patent and Trademark Office issued the patent on January 2, 2025, under publication number US-2025-0000846-A1. This achievement underscores Annovis Bio’s commitment to advancing innovative solutions for neurological health.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.